On June 26, 2026, Everest Medicines announced that China's NMPA had accepted the biologics marketing application for lerodalcibep (R&D code LIB003, US brand name LEROCHOL). Just half a year earlier, the US FDA had approved it on December 12, 2025. A PCSK9 lipid-lowering drug approved in the US with its Chinese marketing application accepted — on progress alone, this is a fairly smooth asset.
But smooth does not mean easy. This article wants to make one thing clear: lerodalcibep is an asset with high certainty on clinical efficacy and registration, yet its value in China depends almost entirely on the one thing it is worst at telling a story about — commercialization. It is not China's first PCSK9 but a latecomer that filed after seven same-class drugs had already been approved one after another; it is entering a market where prices have been beaten to the floor, leading brands have long been on the NRDL, and next-generation oral drugs are knocking at the door.
1. What kind of molecule is this, and who sells it in China
Lerodalcibep's mechanism itself has nothing new — it is a PCSK9 inhibitor that binds and inhibits the PCSK9 protein, preventing degradation of LDL receptors on the surface of liver cells and thus pulling down "bad cholesterol" (LDL-C) in the blood. This pathway has been repeatedly validated by human genetics and several marketed drugs, and is one of the most certain targets in lipid-lowering.
Its difference lies in its form: lerodalcibep is a recombinant fusion protein joining a PCSK9-binding domain to human serum albumin, extending its half-life so that it achieves once-monthly, small-volume subcutaneous injection that patients can self-administer. More crucially, it has a relatively long room-temperature storage window — the US label requires routine refrigeration at 2–8°C, but allows storage at 20–25°C room temperature in the original package for up to 3 months after removal from the refrigerator. This is uncommon for a large biologic and clearly reduces cold-chain pressure (though it does not entirely escape the cold chain). These two points are the physical basis for its entire differentiation story.
The originator is LIB Therapeutics in the US. In September 2023, Hasten obtained development and commercialization rights for Greater China through a collaboration worth about US$325 million in total. In December 2025, Everest Medicines obtained an exclusive Greater China license from Hasten — an upfront of about US$29 million, plus up to US$30 million in development/regulatory milestones and up to US$280 million in sales milestones, plus royalties. In other words, Everest stands at the very end of this rights chain: it is the final licensee, its currently disclosed rights are limited to development, registration and commercialization in Greater China, and global value mainly does not lie in its hands.
Everest Medicines itself is a Hong Kong-listed domestic company operating on an in-licensing + development + commercialization model, already selling products such as Nefecon (for IgA nephropathy), with a target of more than RMB 15 billion in revenue and more than 20 commercial products by 2030. It has cash, a team and a commercialization platform — meaning that for a single-product in-license like lerodalcibep, neither money nor organization is a constraint. The real problem lies elsewhere.
2. The Chinese market: the pool is huge, but the gap is not in "drugs"
First the good side. China's population with dyslipidemia is enormous — Everest cites about 400 million people with dyslipidemia, of whom only about 14% actually receive lipid-lowering treatment. Add the large atherosclerotic cardiovascular disease (ASCVD) secondary prevention population and patients with familial hypercholesterolemia, and the potentially treatable base is one any pharma company would covet.
On efficacy, lerodalcibep holds up too. US approval was based on the LIBerate Phase 3 program, including 3 randomized, double-blind, placebo-controlled studies (about 2,017 patients in total), with more than 2,900 patients enrolled across the whole program and more than 2,400 entering a 72-week open-label extension. Its core study, LIBerate-HR, was a 52-week randomized double-blind controlled study across 66 centers in 11 countries: monthly 300 mg injections lowered LDL-C by about 56% at Week 52 and about 62% on the Week 50/52 mean, with more than 90% of patients reaching guideline-recommended targets. In the Chinese Phase 3, it lowered LDL-C by 65.9% at Week 12, with more than 95% of subjects reaching the dual targets of China's lipid management guidelines. Safety was generally manageable: injection-site reactions were mild (about 6.9% vs 0.3% on placebo). One point needs specific clarification: as a fusion protein, it does induce detectable anti-drug antibodies — the US label shows that about 15.1% of patients in the 52-week study developed anti-drug antibodies (about 22.8% of them neutralizing), and about 11.3% in the 24-week HeFH study (about 55.6% of them neutralizing); but these antibodies were not found to have a clinically significant effect on PK, PCSK9 inhibition, LDL-C efficacy or safety. That is, its immunogenicity is "detectable but without significant clinical impact", not "absent".
But that is precisely the problem: China's gap was never "no potent lipid-lowering drugs". Statins, ezetimibe, plus several marketed PCSK9 inhibitors — the "drugs" for potent lipid lowering have long been complete. The real gap is that treatment rates and target-attainment rates are too low — large numbers of high-risk patients are untreated or not at target. This is a gap in access, adherence, education and payment, not a gap in molecular scarcity. Whether lerodalcibep can win depends on whether it can turn this uncovered population into prescriptions, not on how many more points of LDL-C it can lower.
3. What it has to squeeze into is a red ocean that has already fought a price war
This is the passage in the whole analysis most deserving of bold type. Before lerodalcibep filed, China had already approved seven PCSK9-related drugs (six monoclonal antibodies + one siRNA), and even if all goes smoothly it won't be approved until 2027 at the earliest — an out-and-out latecomer. Lining up the rivals:
- Evolocumab (Repatha, Amgen) and alirocumab (Praluent, Sanofi): two imported monoclonal antibodies long on the NRDL, with unit prices pressed to about RMB 300 per injection and annual costs of about RMB 10,000; and both are backed by cardiovascular outcome studies (FOURIER, ODYSSEY). Notably, Praluent withdrew from the Chinese market in August 2025 — in this red ocean, even veteran players have begun to leave.
- Tafolecimab (Innovent): China's first fully human anti-PCSK9 monoclonal antibody, approved August 2023 and entering the NRDL in 2024 with a price cut of nearly half.
- Ongericimab (Junshi): approved 2024, and in May 2025 further approved for heterozygous familial hypercholesterolemia and statin-intolerant patients — China's first PCSK9 explicitly indicated for statin intolerance.
- Ebronucimab (Yixining®, Akeso): approved September 2024 for primary/mixed/heterozygous familial hypercholesterolemia, included in the 2025 NRDL.
- Recaticimab (Aixin'an®, Hengrui): approved January 2025, billed as the world's first ultra-long-acting PCSK9 monoclonal antibody, with dosing intervals stretching to every 4 weeks and even once every 8 weeks.
- Inclisiran sodium (Leqvio, Novartis): an siRNA needing only one injection every six months — on the dimension of "adherence/injection frequency", it is even tougher than a monthly product.
In other words, lerodalcibep faces a market where the price floor has been welded shut and leading brands already hold the NRDL and prescribing habits, with rivals including both NRDL-listed domestic monoclonal antibodies and ultra-long-acting products like Hengrui's that stretch the interval to once every 8 weeks. Its biggest selling point — monthly self-injection and a relatively long room-temperature window — is a real convenience advantage, especially meaningful for out-of-hospital pharmacies, dual-channel and primary-care settings; but it is a story of "convenience", not of "better efficacy". Its LDL-C reduction is of the same magnitude as marketed monoclonal antibodies, not superior.
4. The registration gate: almost all green, with just one place to lower expectations
If the commercial side is mostly red lights, the registration side is almost green all the way. Breaking out the key gates:
| Gate | Assessment | Explanation |
|---|---|---|
| Completeness of the filing dossier | Positive | Complete global data + a China Phase 3; a solid dossier |
| Regulatory precedent | Positive | Seven same-class drugs approved, LDL-C surrogate endpoint accepted, a clear path |
| Safety database | Positive | Approval based on 3 randomized controlled studies (about 2,017 patients); the full LIBerate program had more than 2,900 patients, with more than 2,400 entering a 72-week extension |
| Clinical approval risk | Low | Clinical work completed, marketing application accepted |
| Safety / immunogenicity | Manageable | Detectable anti-drug/neutralizing antibodies, but no clinically significant impact on efficacy or safety seen; injection reactions mild |
| Room for expedited review | Limited | Ordinary hypercholesterolemia is not a typical indication for acceleration; standard review expected, so don't count on acceleration to win time |
The conclusion is direct: approval of lerodalcibep in 2027 is a high-probability event; uncertainty in the timeline comes mainly from the pace of standard review and local execution steps such as port inspection and batch release for imported biologics in China, not from whether review itself will "get stuck". Everest barely needs to worry about the molecule at this step.
5. For Everest, what exactly is the logic of this asset?
It must be said honestly: lerodalcibep is not a story of "get it working in China first, then take it global". Everest's currently disclosed rights are limited to development, registration and commercialization in Greater China, and global value mainly does not lie in its hands. So its value to Everest is, from start to finish, one thing — selling it in Greater China. The inflection point for value realization is approval in 2027 plus subsequent NRDL access. Chinese patent protection runs to 2039, giving it an exclusivity window of more than ten years — the underlying support for the commercial model to work.
So why would Everest in-license a "seventh place"? The reasonable interpretation is that this is a low-risk portfolio supplement, not a blockbuster gamble. An upfront of under US$30 million is an affordable price for a company with marketed products, cash flow and a target of more than RMB 10 billion in revenue by 2030; and the asset itself carries almost zero development risk. What it is betting on is using the convenience of a relatively long room-temperature window to capture the incremental slice of the 86% untreated population that is sensitive to out-of-hospital and primary-care channels.
Everest's existing commercialization capability is built mainly in nephrology (Nefecon), autoimmunity and anti-infectives. A PCSK9 lipid-lowering drug has to fight in cardiology, endocrinology and the broad primary-care/out-of-hospital market — a completely different team and a completely different set of customer relationships. The relatively long room-temperature window does lower the threshold for out-of-hospital distribution, but "can be distributed" doesn't equal "will sell". Whether Everest builds its own cardiovascular sales team or leans on third parties / co-promotion is a choice far more important than the molecule itself, and directly determines whether this in-license ultimately makes or loses money.
6. Manufacturing and supply: the room-temperature window is a real advantage, but cost is real pressure
On manufacturing, lerodalcibep's commercial process has taken shape with US approval, and this risk has essentially been absorbed by the originator. In the early stage in China, Everest will most likely supply imported finished product, needing to put in place the inspection, batch release and release pathway for imported biologics — an execution issue, not a technical one. In the medium to long term, if volume grows, it can then consider whether to localize manufacturing and transfer technology.
Its manufacturing attribute most worth highlighting is still that relatively long room-temperature storage window. Large biologics generally depend on a 2–8°C cold chain; lerodalcibep likewise requires refrigerated storage, but allows storage at 20–25°C in the original package for up to 3 months after removal from the refrigerator, clearly reducing (though not entirely escaping) cold-chain pressure; paired with a prefilled syringe (expected to launch in the US in spring 2026) and a later autoinjector, this makes it naturally suited to pharmacies, dual-channel and home self-injection settings. In China, this matches exactly the real pain point of "poor access in primary care and out of hospital".
But the other side of the coin is cost. Manufacturing costs for biologics are inherently higher than for small molecules, and prices in the PCSK9 category have already been pressed very low by national negotiation. For lerodalcibep to enter the NRDL and scale, it will almost inevitably have to price close to marketed products, which will make its unit margin quite tight — its commercial model is highly sensitive to scale of volume. Without volume, unit economics will look ugly.
7. Timeline and funding: almost no anxiety on this front
Unlike most domestic biotechs, Everest faces no "running out of cash" time pressure on this project. It is a listed company with products already generating revenue, the cost of in-licensing lerodalcibep (upfront plus milestones) is small relative to its size, and the company's operations don't depend on this one product for financing. The key dates are clear:
2023.09 — Hasten obtains Greater China rights for about US$325 million
2024.03 — China clinical trial application accepted by CDE
2025.12 — US FDA approval; Everest obtains an exclusive Greater China license from Hasten
2026.06 — China marketing application accepted by NMPA (latest progress)
2027 (expected) — Potential approval in mainland China, followed by NRDL access and scale-up
What really decides whether this deal pays off is not "can it launch", but after launch how low NRDL negotiation pushes the price, whether channels can be built quickly, and in which year oral PCSK9 enters China. Everest needs to think through contingency plans for all three before approval in 2027.
8. Five priority actions
Settle the channel first, then everything else
Decide before approval whether cardiology/endocrinology channels will be built in-house or through partnership — the first decisive factor for this in-license. The access advantage brought by the relatively long room-temperature window only pays off once it lands in out-of-hospital and primary-care channels; otherwise it is empty talk.
Turn "convenience" into a quantifiable point of difference
Use real-world data on adherence, self-injection success rates and out-of-hospital accessibility to support a story marketed monoclonal antibodies can't tell, rather than fighting rivals head-on on LDL-C reduction.
Seriously evaluate the feasibility of adding cardiovascular outcome evidence
The lack of cardiovascular hard endpoints is its most concrete weakness when bargaining against imported monoclonal antibodies; even a large real-world study is better than nothing at all.
Nail down the NRDL price floor and break-even line in advance
Biologic costs are high and category prices have been pressed low; the size of the price cut for NRDL entry directly determines unit economics, and a red line of "won't accept below this price" must be set.
Keep a close watch on oral PCSK9 progress as an exit trigger
Once oral PCSK9 is approved in China and enters guidelines, the convenience narrative of injectables will be repriced — this should be a pre-set reassessment point, not something reacted to after the fact.
Conclusion
Lerodalcibep is a rare "contrast" asset: from molecule and efficacy to registration certainty, it is so clean it is hard to fault (though immunogenicity and other issues still need continued post-marketing observation); yet put it back into China's PCSK9 red ocean and its story immediately changes from "does this drug work" to "will this drug sell". It is not a pioneer but a latecomer; its weapon is not efficacy but convenience; its rivals are not only same-class monoclonal antibodies already on the NRDL, but also oral drugs on the way.
For Everest, this is a portfolio supplement with a controllable cost and back-loaded risk: limited downside, but upside firmly held down by the price war and the missing cardiovascular evidence. Whether it ultimately succeeds depends almost not at all on the molecule itself, but on whether Everest is willing and able to build, for an entirely new therapeutic area, a commercial playbook completely different from its existing nephrology DNA. The answer to this exam lies not in the lab, but with the sales force and at the negotiating table.
Data & Sources
Compiled and analyzed from public information; clinical data, deal terms, regulatory progress and market judgments all come from company announcements, regulatory disclosures and public reports and may be updated over time. The views herein are strategic assessments based on available information and do not constitute investment, medical or business decision advice. Drug information is subject to the prescribing information approved by the national drug regulatory authority.